BRAF and colorectal cancer: Interestingly, high ezrin expression was previously correlated with BRAFV600E mutation status in colorectal cancer since high ezrin immunohistochemical staining was found predominantly in BRAFV600E-mutated tumours (52%) in comparison with BRAF wild-type tumours (17%) [29].